Another study investigated the role of SHR-1701, a bifunctional agent composed of an IgG4 mAb, targeting PD-L1, fused with the extracellular domain of TGF-βIIR, in addition to SoC chemotherapy, for unresectable, locally advanced or metastatic HER2-negative GC/GEJC patients. Here, ERBB2 is linked to gastric cancer.